The 2015 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC)

Fred Saad, Kim Chi, Antonio Finelli, Sebastien Hotte, Jonathan Izawa, Anil Kapoor, Wassim Kassouf, Andrew Loblaw, Scott North, Ricardo Rendon, Alan So, Nawaid Usmani, Eric Vigneault, Neil Eric Fleshner


Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance of optimizing the use of these agents, a multidisciplinary team approach is highly recommended.


castration-resistant prostate cancer

Full Text:



Comments on this article

View all comments
 |  Add comment